ArticleWorld journal of urology2025
Correction: Can we rely on magnetic resonance imaging for prostate cancer detection and surgical planning? Comprehensive analysis of a large cohort of patients undergoing transperineal mapped biopsies.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Focal Cryotherapy in Prostate Cancer. Does Gleason Impact Results?International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
- Erratum for
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate MRI and histological concordance in prostate cancer (PCa) identification via mapped transperineal biopsies. METHODOLOGY: Retrospective per-lesion analysis of patients undergoing MRI and transperineal biopsy at the Valencian Institute of Oncology (2016-2024) using CAPROSIVO PCa data. Patients underwent MRI, with or without regions of interest (ROI), followed by transperineal biopsies (3-5 cores/ROI, 20-30 systematic). Sensitivity (Se), specificity (Sp), negative predictive value (NPV), positive predictive value (PPV), and area under the curve (AUC) were calculated, considering PI-RADS 3 lesions as positive or negative. Gleason Grade Group (GG) > 1 defined clinically significant PCa (csPCa).
results1817 lesions were analyzed from 1325 patients (median age 67, median PSA 6.3 ng/ml). 53% MRI were negative, GG > 1 prevalence was 29.1%. MRI-negative cases showed varying PCa rates: 57.4% negative, 34.3% GG 1, and 8.3% GG > 1. PI-RADS 3 lesions had mixed outcomes: 45.6% benign, 29.5% GG 1, and 24.9% GG > 1. 9.2% PI-RADS 4-5 lesions were negative, 23% GG 1, and 67.8% GG > 1. For PI-RADS 3 lesions considered positive, Se, Sp, NPV, PPV, and AUC were 84.9%, 68.4%, 91.7%, 52.6%, and 0.77 respectively. Considering PI-RADS 3 as negative yielded 70.6% Se, 86.2%, Sp, 87.7% NPV, 67.8% PPV, and 0.78 AUC.
conclusionMRI and mapped prostate biopsies exhibited moderate concordance. MRI could miss up to one in ten csPCa foci and misinterpret one in two ROIs. Careful MRI interpretation is crucial for optimizing patient care.
Indexed as
Identifiers
40072605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.